The trajectory of Viagra, formerly marketed by copyright, presents a fascinating case study for investors considering the drug sector. Despite its groundbreaking success and generation of countless in earnings , the patent end has opened the door for generic medications, significantly reducing profit prospects . This transition raises questions abo